By Doug Macron

Australia's Benitec this week announced that it has expanded its pipeline to include a treatment for oculopharyngeal muscular dystrophy, or OPMD, which will be developed in collaboration with the Royal Holloway University London.

The company separately said that it is also exploring a potential partnership with Chinese investigators who have independently conducted research on expressed RNAi-based treatments for pain, an indication at the forefront of Benitec's drug-development efforts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.